At a Glance: BRCA1 & BRCA2 Genetic Testing
- Sample Required: Blood (EDTA) or Saliva (Oragene kit)
- Fasting Rules: No fasting required
- Turnaround Time (TAT): 10–14 business days
- Base Cost: [Insert Current 2026 Price]
Understanding Hereditary Breast Cancer
Breast cancer remains the most common cancer among women in India, with an estimated 2.4 million new cases projected by 2026. While most cases are sporadic, approximately 5–10% are hereditary, driven by mutations in high-penetrance genes such as BRCA1 and BRCA2. These genes are critical for DNA repair; when mutated, they significantly increase lifetime risk for breast and ovarian cancers.
At DNA Labs India, we offer comprehensive BRCA1 and BRCA2 genetic testing using Next-Generation Sequencing (NGS) and Whole Exome Sequencing (WES) to identify pathogenic variants. Our ISO 9001 certified laboratory ensures accurate, timely, and confidential results, empowering you with actionable insights for proactive cancer prevention and management.
BRCA1 and BRCA2: The Guardians of Genomic Integrity
BRCA1 (BReast CAncer gene 1) and BRCA2 (BReast CAncer gene 2) are tumor suppressor genes that encode proteins responsible for repairing double-strand DNA breaks. When these genes harbor deleterious mutations, the repair mechanism fails, leading to genomic instability and increased cancer susceptibility.
| Feature | BRCA1 | BRCA2 |
|---|---|---|
| Chromosomal Location | 17q21 | 13q13 |
| Lifetime Breast Cancer Risk | ~72% | ~69% |
| Ovarian Cancer Risk | ~44% | ~17% |
| Associated Cancers | Breast, Ovarian, Pancreatic, Prostate | Breast, Ovarian, Pancreatic, Prostate, Melanoma |
Mutations in these genes are inherited in an autosomal dominant pattern, meaning a 50% chance of passing the mutation to offspring. Genetic testing identifies these mutations, enabling personalized surveillance and risk-reduction strategies.
Who Should Consider BRCA Genetic Testing?
The National Comprehensive Cancer Network (NCCN) guidelines recommend genetic counseling and testing for individuals with a personal or family history suggestive of hereditary breast and ovarian cancer syndrome. Key indicators include:
- Diagnosis of breast cancer at age ≤50 years
- Triple-negative breast cancer diagnosed at age ≤60 years
- Two or more primary breast cancers in the same individual
- Known BRCA1/BRCA2 mutation in the family
- Ashkenazi Jewish ancestry with a family history of breast/ovarian cancer
- Male breast cancer at any age
- Ovarian cancer, pancreatic cancer, or metastatic prostate cancer
Note: Genetic testing is a personal decision. It is recommended to undergo pre- and post-test genetic counseling to understand the implications, benefits, and limitations.
Symptoms and Risk Factors of Hereditary Breast Cancer
While BRCA mutations do not cause symptoms themselves, they elevate cancer risk. Early detection through regular screening is vital. Common breast cancer symptoms include:
- New lump in the breast or underarm
- Thickening or swelling of part of the breast
- Skin dimpling or irritation
- Nipple discharge (other than breast milk) or inversion
- Redness or flaky skin on the nipple or breast
Risk factors for hereditary breast cancer include:
| Risk Factor | Description |
|---|---|
| Family History | First-degree relatives with breast/ovarian cancer, especially at young age |
| Genetic Mutations | Pathogenic variants in BRCA1, BRCA2, or other high-penetrance genes |
| Ethnicity | Ashkenazi Jewish, Norwegian, Dutch, Icelandic populations have higher prevalence |
| Personal History | Previous breast cancer, atypical hyperplasia, or lobular carcinoma in situ |
The BRCA Genetic Testing Process at DNA Labs India
Our testing protocol follows international guidelines and utilizes advanced NGS technology to ensure high sensitivity and specificity. The process is simple:
- Sample Collection: A blood sample (EDTA) or saliva sample (Oragene kit) is collected at our collection centers or via home collection.
- DNA Extraction and Sequencing: DNA is extracted and sequenced using NGS/WES to analyze the entire coding regions of BRCA1 and BRCA2, including intron-exon boundaries.
- Variant Classification: Detected variants are classified as pathogenic, likely pathogenic, variant of uncertain significance (VUS), likely benign, or benign according to ACMG guidelines.
- Report Generation: A comprehensive report is provided, including clinical interpretation and recommendations for risk management.